<?xml version='1.0' encoding='utf-8'?>
<document id="25816344"><sentence text="Ligand-target prediction by structural network biology using nAnnoLyze." /><sentence text="Target identification is essential for drug design, drug-drug interaction prediction, dosage adjustment and side effect anticipation" /><sentence text=" Specifically, the knowledge of structural details is essential for understanding the mode of action of a compound on a target protein" /><sentence text=" Here, we present nAnnoLyze, a method for target identification that relies on the hypothesis that structurally similar binding sites bind similar ligands" /><sentence text=" nAnnoLyze integrates structural information into a bipartite network of interactions and similarities to predict structurally detailed compound-protein interactions at proteome scale" /><sentence text=" The method was benchmarked on a dataset of 6,282 pairs of known interacting ligand-target pairs reaching a 0" /><sentence text="96 of area under the Receiver Operating Characteristic curve (AUC) when using the drug names as an input feature for the classifier, and a 0" /><sentence text="70 of AUC for &quot;anonymous&quot; compounds or compounds not present in the training set" /><sentence text=" nAnnoLyze resulted in higher accuracies than its predecessor, AnnoLyze" /><sentence text=" We applied the method to predict interactions for all the compounds in the DrugBank database with each human protein structure and provide examples of target identification for known drugs against human diseases" /><sentence text=" The accuracy and applicability of our method to any compound indicate that a comparative docking approach such as nAnnoLyze enables large-scale annotation and analysis of compound-protein interactions and thus may benefit drug development" /><sentence text=" " /></document>